Trailing Twelve Month EBITDA Clause Samples

The 'Trailing Twelve Month EBITDA' clause defines how a company's earnings before interest, taxes, depreciation, and amortization (EBITDA) are calculated over the most recent twelve-month period. This clause typically specifies the method for aggregating financial results from the past year, often using monthly or quarterly financial statements to determine the total EBITDA. By standardizing the calculation period and method, the clause ensures consistency and comparability in financial assessments, which is crucial for evaluating performance, setting covenants, or determining eligibility for transactions.
POPULAR SAMPLE Copied 6 times
Trailing Twelve Month EBITDA. EBITDA at not less than the amounts set forth below at the indicated dates, measured as of the end of each fiscal quarter for the 12 months then-ending, as follows: Fiscal Quarter Date Minimum EBITDA Amount June 30, 2010 $3,500,000.00 September 30, 2010 and thereafter $4,000,000.00
View SourceView Similar (2)
Trailing Twelve Month EBITDA. (of Resmed and RMT) A. Net Income, plus $__________________ B. any non-operating, non recurring loss (not to exceed $2,000,000) reflected in such Net Income, minus $__________________ C. any non-operating, nonrecurring gain (not to exceed $2,000,000) reflected in such Net Income, plus $__________________ D. Interest Expense, plus $__________________ E. payment or provision for income taxes, plus $__________________ F. depreciation, amortization and other non-cash expenses $__________________ G. total Trailing Twelve Month EBITDA (III.A + B - C + D + E +F) $__________________ Minimum Required $ 15,000,000
View Source
Trailing Twelve Month EBITDA. Maintain, measured as of the end of each fiscal quarter, trailing 12 month EBITDA of at least the following: September 30, 2010 $(25,000,000) December 31, 2010 $0 March 31, 2011 and thereafter $5,000,000 or as established by Bank based on projections provided by Borrower EBITDA shall be deemed to be $3,379,000 for the fiscal quarter ending September 30, 2009, $6,237,000 for the fiscal quarter ending December 31, 2009, and ($7,803,000) for the fiscal quarter ending March 31, 2010.
View Source
Trailing Twelve Month EBITDA. Commencing on the Closing Date and ending on December 31, 2024, the Borrowers shall maintain EBITDA (on a trailing basis beginning with the month ending September 30, 2023, and as of the August 30, 2024 measurement period and all future periods, on a trailing twelve-month basis) in accordance with the schedule immediately below: September 30th 2023 US $141,662.52 October 31st 2023 US $544,723.34 November 30th 2023 US $904,951.74 December 31st 2023 US $1,052,705.73 January 31st 2024 US $1,455,422.43 February 29th 2024 US $1,928,944.68 March 30th 2024 US $2,388,870.87 April 30th 2024 US $2,873,709.93 May 31st 2024 US $3,428,882.94 June 30th 2024 US $3,954,979.93 July 31st 2024 US $4,492,420.78 August 31st 2024 US $5,047,190.73 September 30th 2024 US $5,388,550.09 October 31st, 2024 US $5,561,637.25 November 30th 2024 US $5,846,881.04 December 31st 2024 US $6,236,869.98 If the trailing-twelve month EBITDA falls below the scheduled thresholds above, the Loan Parties shall cause BBX Capital, Inc. to immediately provide a Permitted Financial Covenant Equity Contribution. It is agreed that any Permitted Financial Covenant Equity Contribution shall be included for purposes of the calculation of Excess Availability and compliance with subsection 12(q) under this Agreement.
View Source

Related to Trailing Twelve Month EBITDA

  • Adjusted EBITDA The 2019 adjusted EBITDA for the Affiliated Club Sellers shall total an aggregate of not less than $10,700,000.

  • Measurement Period In this Agreement, unless the contrary intention appears, a reference to:

  • Consolidated EBITDA With respect to any period, an amount equal to the EBITDA of Borrower and its Subsidiaries for such period determined on a Consolidated basis.

  • EBITDA The term “EBITDA” shall mean, with respect to any fiscal period, “Consolidated EBITDA” as defined in the Credit Agreement, provided that the following should also be excluded from the calculation of EBITDA to the extent not already excluded from the calculation of Consolidated EBITDA under the Credit Agreement: (i) Non-Cash Charges (as defined in the Credit Agreement) related to any issuances of equity securities; (ii) fees and expenses relating to the Acquisition; (iii) financing fees (both cash and non-cash) relating to the Acquisition; (iv) covenant-not-to-compete payments to certain members of the Company’s senior management and related expenses; (v) expenses (or any portion thereof) incurred outside of the ordinary course of business that are approved by the Board which the Board determines in its good faith discretion are in the best interest of the Company but which will have a disproportionately adverse impact on the Company’s short term financial performance, affecting the Company’s ability to achieve financial targets related to the vesting of the Class C Units under the Incentive Unit Subscription Agreements or the Company’s annual bonus plan; (vi) costs and expenses incurred in connection with evaluating and consummating acquisitions not contemplated by the Company’s annual plan, as such plan is approved by the Board in good faith; (vii) related party expenditures that are subject to the prior written consent of the Majority Executives pursuant to Section 2.3(a) of the Securityholders Agreement but have failed to receive such consent; (viii) advisors’ fees and expenses incurred outside the ordinary course of business related solely to Vestar’s activities that are unrelated to the Company; (ix) costs associated with any put option or call option contemplated by any Rollover Subscription Agreement or Incentive Unit Subscription Agreement; (x) costs associated with any proposed initial Public Offering or Sale of the Company (as such terms are defined in the Securityholders Agreement); (xi) expenses related to any litigation arising from the Acquisition; (x) management fees and costs related to the activities giving rise to such fees that are paid to, paid for or reimbursed to Vestar and its Affiliates; and (xii) material expenditures or incremental expenditures inconsistent with prior practice (to the extent that prior practice is relevant) required by Board (where Management Managers (as defined in the Securityholders Agreement) unanimously dissent) unless such expenditures are reasonably likely to result in any benefit (whether economic or non-economic) to the Company as determined by the Board in its good faith discretion.

  • Interest Expense Coverage Ratio The Borrower will not permit the ratio of (a) Consolidated EBITDA to (b) Consolidated Interest Expense, in each case for any period of four consecutive fiscal quarters ending after the Effective Date, to be less than 4.0 to 1.0.